ConductScience.org, home

Paper37589596

Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso.

Ouedraogo A and 16 others. J Pediatric Infect Dis Soc, 2023. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso. Papers, record 37589596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37589596

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso.
PubMed
Journal
J Pediatric Infect Dis Soc
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.57
iCite
Revised in PubMed
2023-10-04
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ouedraogo AAlphonse
2Diarra AAmidou
3Nébié IIssa
4Barry NNouhoun
5Kabore JMJean Moise
6Tiono ABAlfred B
7Datta SShrimati
8Liang YYuanyuan
9Mayo IIfayet
10Oshinsky JJJennifer J
11Tracy JKJ Kathleen
12Girmay TTsion
13Pasetti MFMarcela F
14Jamka LPLeslie Phttps://orcid.org/0000-0003-4997-4570
15Neuzil KMKathleen M
16Sirima SBSodiomon B
17Laurens MBMatthew Bhttps://orcid.org/0000-0003-3874-581X

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Typhoid FeverMajor topic
Typhoid-Paratyphoid VaccinesMajor topic
Humans
Child
Infant
Vaccines, Conjugate
Burkina Faso
Antibody Formation
Immunoglobulin A
Immunoglobulin G
Antibodies, Bacterial

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
OPP1151153Bill and Melinda Gates FoundationPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07624175Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina FasoBackground

Source ClinicalTrials.gov

Download CSV of trials

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134384540Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.Lancet2021https://conductscience.org/library/papers/34384540PubMed
235961356Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial.Lancet Glob Health2022https://conductscience.org/library/papers/35961356PubMed
328965718
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Lancet2017https://conductscience.org/library/papers/28965718PubMed
411320385The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.N Engl J Med2001https://conductscience.org/library/papers/11320385PubMed
534625288
Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination.
Vaccine2021https://conductscience.org/library/papers/34625288PubMed
625870324
Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
Clin Infect Dis2015https://conductscience.org/library/papers/25870324PubMed
724669583WHO Expert Committee on Biological Standardization. Sixty-third report.World Health Organ Tech Rep Ser2014https://conductscience.org/library/papers/24669583PubMed
833176205Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.Int J Infect Dis2021https://conductscience.org/library/papers/33176205PubMed
933180929Vi-specific serological correlates of protection for typhoid fever.J Exp Med2021https://conductscience.org/library/papers/33180929PubMed
1034082090Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial.Int J Infect Dis2021https://conductscience.org/library/papers/34082090PubMed
1134678198Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.Lancet Glob Health2021https://conductscience.org/library/papers/34678198PubMed
1234525285Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.N Engl J Med2021https://conductscience.org/library/papers/34525285PubMed
1331781100IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model.Front Immunol2019https://conductscience.org/library/papers/31781100PubMed

Download CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
41372809High prevalence of multi-drug resistant H58 Salmonella Typhi and emerging fluoroquinolone resistance among febrile children in Nairobi County, Kenya.BMC Infect Dis2025https://conductscience.org/library/papers/41372809PubMed
40034570Immunogenicity and reactogenicity of a booster dose of a typhoid conjugate vaccine (TCV) in Malawian pre-school children.EClinicalMedicine2025https://conductscience.org/library/papers/40034570PubMed
39483419Genotypic Diversity among Salmonella Typhi Isolated from Children Living in Informal Settlements in Nairobi, Kenya.Int J Clin Microbiol2024https://conductscience.org/library/papers/39483419PubMed
39257585The use of controlled human infection models to identify correlates of protection for invasive Salmonella vaccines.Front Immunol2024https://conductscience.org/library/papers/39257585PubMed
39038733Longevity of immune response after a single dose of typhoid conjugate vaccine against Salmonella Typhi among children in Hyderabad, Pakistan.Int J Infect Dis2024https://conductscience.org/library/papers/39038733PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD79A973PubTator's text mininghttps://conductscience.org/library/genes/973

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37589596

GET https://conductscience.org/api/papers/v1/37589596/authors